4. (Original) The polypeptide of claim 1, wherein the wild type ricin A chain first globular domain sequence is SEQ ID NO:2 or a variant thereof.

5. (Original) The polypeptide of claim 1, wherein the polypeptide sequence comprises SEQ ID NO:3, SEQ ID NO:4, or a variant thereof.

6. (Original) The polypeptide of claim 1, wherein the polypeptide sequence is substantially identical to SEQ ID NO:3 or SEQ ID NO:4.

7. (Original) The polypeptide of claim 1, wherein the polypeptide sequence lacks a hydrophobic loop that corresponds to the hydrophobic loop of wild type ricin A chain.

8. (Original) The polypeptide of claim 1, wherein the polypeptide sequence comprises at least one amino acid mutation, substitution, deletion, or a combination thereof, when compared to an amino acid sequence of ricin.

9. (Original) The polypeptide of claim 1, made by recombinant DNA techniques.

10. (Original) The polypeptide of claim 1, made by proteolytically cleaving the first globular domain and the second globular domain of ricin A chain and then purifying the first globular domain.

B1 11-13. (Cancel).

14. (Original) A pharmaceutical composition comprising at least one polypeptide or variant of claim 1 in an immunogenic amount and a pharmaceutically acceptable vehicle.

15. (Original) The pharmaceutical composition of claim 14, and further comprising an adjuvant.

16. (Original) The pharmaceutical composition of claim 14, wherein the composition is capable of eliciting an immune response when administered to a subject.

17. (Original) The pharmaceutical composition of claim 16, wherein the immune response is a protective immune response.

18. (Currently amended) A pharmaceutical composition comprising at least one antibody [of claim 12] raised against the polypeptide or variant of claim 1 in a therapeutically effective amount and a pharmaceutically acceptable vehicle.

19-23. (Cancel).

24. (Original) A kit comprising at least one of the following

(a) an isolated polypeptide or variant thereof comprising a polypeptide sequence having substantial identity to a wild type ricin A chain first globular domain sequence and lacks detectable N-glycosidase-rRNA activity or exhibits reduced N-glycosidase-rRNA activity as compared to a control;

B1

(b) an antibody raised against the isolated polypeptide or variant of (a);

(c) a pharmaceutical composition comprising at least one polypeptide or variant of (a) in an immunogenic amount and a pharmaceutically acceptable vehicle; and

(d) a vaccine comprising an immunogenic amount of at least one polypeptide or variant of (a);

packaged together with instructions for use.